Apellis Pharmaceuticals

Apellis Pharmaceuticals company information, Employees & Contact Information

Explore related pages

Apellis Pharmaceuticals email format Apellis Pharmaceuticals management contacts

Related company profiles:

At Apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases where patients have few or no treatment options available. Our programs across ophthalmology, nephrology, hematology, and neurology are further exploring what is possible by targeting C3. You can view our community guidelines here: Community guidelines: http://bit.ly/476Q8

Company Details

Employees
783
Founded
-
Address
100 Fifth Ave, 3rd Floor,switzerland
Phone
502-241-4114
Email
in****@****lis.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
apellis.com
Keywords
Targeted C3 Therapies, Complement System, Hematology, Ophthalmology, Nephrology, Paroxysmal Nocturnal Hemoglobinuria (PNH), Geographic Atrophy (GA), C3 Glomerulopathy (C3G), Cold Agglutinin Disease (CAD), Gene Therapy, Neurology, Amyotrophic Lateral Sclerosis (ALS).
HQ
Waltham, MA
Competitors
Acadia Pharmaceuticals Inc., Alnylam Pharmaceuticals, Sage Therapeutics, Ionis Pharmaceuticals, Inc., Biogen, Alexion Pharmaceuticals, Inc., Vertex Pharmaceuticals, Jazz Pharmaceuticals, Agios Pharmaceuticals, Sarepta Therapeutics.
Looking for a particular Apellis Pharmaceuticals employee's phone or email?

Apellis Pharmaceuticals Questions

News

FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the - GlobeNewswire

FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the GlobeNewswire

Oct. 30 conference call: Apellis will discuss Q3 2025 financial results; webcast replay available 90 days - Stock Titan

Oct. 30 conference call: Apellis will discuss Q3 2025 financial results; webcast replay available 90 days Stock Titan

Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results - Yahoo Finance

Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results Yahoo Finance

Apellis Pharmaceuticals to Host Conference Call for Q2 2025 Financial Results on July 31 - Nasdaq

Apellis Pharmaceuticals to Host Conference Call for Q2 2025 Financial Results on July 31 Nasdaq

Craig Wheeler to Join Apellis Board of Directors - citybiz

Craig Wheeler to Join Apellis Board of Directors citybiz

Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results - The Manila Times

Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results The Manila Times

Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results - Yahoo Finance

Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results Yahoo Finance

Biotech Leader Apellis Pharmaceuticals Announces Triple Conference Schedule for September 2025 - Stock Titan

Biotech Leader Apellis Pharmaceuticals Announces Triple Conference Schedule for September 2025 Stock Titan

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN - GlobeNewswire

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN GlobeNewswire

Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan) - Yahoo Finance

Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan) Yahoo Finance

Apellis Reveals New Insights at Goldman Sachs Healthcare Conference: How to Watch Live - Stock Titan

Apellis Reveals New Insights at Goldman Sachs Healthcare Conference: How to Watch Live Stock Titan

Apellis Pharmaceuticals Appoints Craig Wheeler to Board of Directors - Quiver Quantitative

Apellis Pharmaceuticals Appoints Craig Wheeler to Board of Directors Quiver Quantitative

$300M Deal: Apellis Sells Ex-US Aspaveli Royalties to Sobi in Strategic Rare Disease Partnership - Stock Titan

$300M Deal: Apellis Sells Ex-US Aspaveli Royalties to Sobi in Strategic Rare Disease Partnership Stock Titan

Apellis Pharmaceuticals' SYFOVRE® Approved by Australian TGA for Treatment of Geographic Atrophy - Quiver Quantitative

Apellis Pharmaceuticals' SYFOVRE® Approved by Australian TGA for Treatment of Geographic Atrophy Quiver Quantitative

Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - FinancialContent

Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference FinancialContent

Breakthrough: EMPAVELI Scores Priority FDA Review After 68% Disease Reduction in Rare Kidney Disorders - Stock Titan

Breakthrough: EMPAVELI Scores Priority FDA Review After 68% Disease Reduction in Rare Kidney Disorders Stock Titan

Apellis Reports Strong $709M Revenue as SYFOVRE Sales Surge 120%, Announces Leadership Changes - Stock Titan

Apellis Reports Strong $709M Revenue as SYFOVRE Sales Surge 120%, Announces Leadership Changes Stock Titan

Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street - Sixth Street

Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street Sixth Street

Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration - Yahoo Finance

Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration Yahoo Finance

With complements: C3 inhibition in the clinic - Kolev - Immunological Reviews - Wiley Online Library

With complements: C3 inhibition in the clinic - Kolev - Immunological Reviews Wiley Online Library

Empaveli Approved for Two Rare Kidney Diseases - MPR - Medical Professionals Reference

Empaveli Approved for Two Rare Kidney Diseases - MPR Medical Professionals Reference

68% proteinuria reduction at 1 year — Apellis' EMPAVELI sustains remission in C3G and primary IC‑MPGN at ASN - Stock Titan

68% proteinuria reduction at 1 year — Apellis' EMPAVELI sustains remission in C3G and primary IC‑MPGN at ASN Stock Titan

Apellis Releases Update on Retinal Vasculitis Associated with Pegcetacoplan Injection - HCPLive

Apellis Releases Update on Retinal Vasculitis Associated with Pegcetacoplan Injection HCPLive

FDA approves pegcetacoplan as first treatment for C3 glomerulopathy or IC-MPGN - Contemporary Pediatrics

FDA approves pegcetacoplan as first treatment for C3 glomerulopathy or IC-MPGN Contemporary Pediatrics

FDA Approves Pegcetacoplan for C3G and IC-MPGN - Docwire News

FDA Approves Pegcetacoplan for C3G and IC-MPGN Docwire News

EU CHMP issues negative opinion on Apellis MAA application for pegcetacoplan (Syfovre) injection - Ophthalmology Times Europe

EU CHMP issues negative opinion on Apellis MAA application for pegcetacoplan (Syfovre) injection Ophthalmology Times Europe

FDA Approves Apellis’ Empaveli for C3 Glomerulopathy, Primary Immune Complex Membranoproliferative Glomerulonephritis - Pharmaceutical Executive

FDA Approves Apellis’ Empaveli for C3 Glomerulopathy, Primary Immune Complex Membranoproliferative Glomerulonephritis Pharmaceutical Executive

Georgia Retina Participates in Apellis Pharmaceuticals’ Groundbreaking Clinical Trials for SYFOVRE, the first and only FDA-approved treatment for Geographic Atrophy - Business Wire

Georgia Retina Participates in Apellis Pharmaceuticals’ Groundbreaking Clinical Trials for SYFOVRE, the first and only FDA-approved treatment for Geographic Atrophy Business Wire

Geographic atrophy treatment options ignite debate on concerns, expectations - Healio

Geographic atrophy treatment options ignite debate on concerns, expectations Healio

Apellis Pharmaceuticals (APLS) Reports Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies - StreetInsider

Apellis Pharmaceuticals (APLS) Reports Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies StreetInsider

Empaveli Approved for Self-Administration With New On-Body Injector - Medical Professionals Reference

Empaveli Approved for Self-Administration With New On-Body Injector Medical Professionals Reference

With complements: C3 inhibition in the clinic - Kolev - 2023 - Immunological Reviews - Wiley Online Library

With complements: C3 inhibition in the clinic - Kolev - 2023 - Immunological Reviews Wiley Online Library

Syfovre Approved for Geographic Atrophy Secondary to AMD - Medical Professionals Reference

Syfovre Approved for Geographic Atrophy Secondary to AMD Medical Professionals Reference

SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA) - Stock Titan

SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA) Stock Titan

New data reinforce robust efficacy and safety profile of Aspaveli/Empaveli (pegcetacoplan) for PNH at the EHA2022 Congre - Europa Press

New data reinforce robust efficacy and safety profile of Aspaveli/Empaveli (pegcetacoplan) for PNH at the EHA2022 Congre Europa Press

New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week - The Manila Times

New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week The Manila Times

APLS Stock Price and Chart — NASDAQ:APLS - TradingView

APLS Stock Price and Chart — NASDAQ:APLS TradingView

Apellis Pharmaceuticals (APLS) Stock Price, News & Analysis - MarketBeat

Apellis Pharmaceuticals (APLS) Stock Price, News & Analysis MarketBeat

Metrowest Business Digest for Jan. 5, 2018 - MetroWest Daily News

Metrowest Business Digest for Jan. 5, 2018 MetroWest Daily News

Companies like Apellis Pharmaceuticals

Agios Pharmaceuticals logo - Similar company to Apellis Pharmaceuticals

Agios Pharmaceuticals

654
Jazz Pharmaceuticals logo - Similar company to Apellis Pharmaceuticals

Jazz Pharmaceuticals

3.45K
Acadia Pharmaceuticals Inc. logo - Similar company to Apellis Pharmaceuticals

Acadia Pharmaceutica...

891
Vertex Pharmaceuticals logo - Similar company to Apellis Pharmaceuticals

Vertex Pharmaceuticals

6.09K
Ionis Pharmaceuticals, Inc. logo - Similar company to Apellis Pharmaceuticals

Ionis Pharmaceutical...

1.27K
Alexion Pharmaceuticals, Inc. logo - Similar company to Apellis Pharmaceuticals

Alexion Pharmaceutic...

5.06K
Sage Therapeutics logo - Similar company to Apellis Pharmaceuticals

Sage Therapeutics

451
Biogen logo - Similar company to Apellis Pharmaceuticals

Biogen

7.60K
Alnylam Pharmaceuticals logo - Similar company to Apellis Pharmaceuticals

Alnylam Pharmaceuticals

2.58K
Sarepta Therapeutics logo - Similar company to Apellis Pharmaceuticals

Sarepta Therapeutics

1.37K

Top Apellis Pharmaceuticals Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant